C4 therapeutics presents clinical data from cohort a of the ongoing phase 1/2 clinical trial of cft7455, a novel ikzf1/3 degrader

– single agent cft7455 induces deep and durable degradation of ikzf1/3 and meaningful decreases in serum free light chain at doses lower than expected based on pre-clinical studies –

CCCC Ratings Summary

CCCC Quant Ranking